| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14a56e82e7ee8111cfcd7565412176b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-15 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185 |
| filingDate |
2005-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4c9dde3f5f5a153fe5676e133c706d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d77ced532820a0ec4e8905059d61d135 |
| publicationDate |
2007-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1765314-A1 |
| titleOfInvention |
Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis |
| abstract |
The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV. |
| priorityDate |
2004-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |